Clinical features of cases (N = 198)
| Sex, n (%) | |
| Female | 119 (60.1) |
| Male | 79 (39.9) |
| Ratio | 1.5 |
| Age at diagnosis, y | |
| Overall | |
| Mean (SD) | 49.0 (18.2) |
| Median | 50.8 |
| Female (n = 119) | |
| Mean (SD) | 45.4 (18.3) |
| Median | 42.7 |
| Male (n = 79) | |
| Mean (SD) | 54.4 (16.8) |
| Median | 57.3 |
| Platelet count at diagnosis, G/L | |
| Mean (SD) | 15.1 (17.1) |
| Median (min-max) | 7.5 (0.0-87.0) |
| At or below 50 G/L | 186 (94.4) |
| Bleeding symptoms at diagnosis, n (%) | |
| Epistaxis | 38 (19.2) |
| Cutaneous bleeding | 154 (77.8) |
| Bleeding from mucous membranes | 90 (45.5) |
| Visceral hemorrhage | 8 (4.0) |
| At least 1 bleeding symptom | 166 (83.8) |
| Days from first symptom to recruitment, mean (SD) | 73.3 (90.1) |
| Frontline treatment, n (%) | |
| Corticosteroids | 159 (80.3) |
| IV Ig | 100 (50.5) |
| Other treatment | 14 (7.1) |
| Overall initial response to treatment* | 164 (82.8) |
| Sex, n (%) | |
| Female | 119 (60.1) |
| Male | 79 (39.9) |
| Ratio | 1.5 |
| Age at diagnosis, y | |
| Overall | |
| Mean (SD) | 49.0 (18.2) |
| Median | 50.8 |
| Female (n = 119) | |
| Mean (SD) | 45.4 (18.3) |
| Median | 42.7 |
| Male (n = 79) | |
| Mean (SD) | 54.4 (16.8) |
| Median | 57.3 |
| Platelet count at diagnosis, G/L | |
| Mean (SD) | 15.1 (17.1) |
| Median (min-max) | 7.5 (0.0-87.0) |
| At or below 50 G/L | 186 (94.4) |
| Bleeding symptoms at diagnosis, n (%) | |
| Epistaxis | 38 (19.2) |
| Cutaneous bleeding | 154 (77.8) |
| Bleeding from mucous membranes | 90 (45.5) |
| Visceral hemorrhage | 8 (4.0) |
| At least 1 bleeding symptom | 166 (83.8) |
| Days from first symptom to recruitment, mean (SD) | 73.3 (90.1) |
| Frontline treatment, n (%) | |
| Corticosteroids | 159 (80.3) |
| IV Ig | 100 (50.5) |
| Other treatment | 14 (7.1) |
| Overall initial response to treatment* | 164 (82.8) |
Response was defined by a platelet count above 30 × 109/L with at least a 2-fold increase from pretreatment count.